Pipeline development has proved frustratingly difficult for cardiology-focused companies like Medtronic, St. Jude Medical (NYSE: STJ ) , and Boston Scientific (NYSE: BSX )
over the last few quarters. St. Jude modified their clinical trial
plans for renal denervation and left atrial appendage closure because of
enrollment worries against competing devices from Medtronic and Boston
Scientific, while Medtronic's renal denervation program failed a pivotal
study and its peripheral drug-coated balloon program has likewise
disappointed.
When it comes to Boston Scientific, challenging
reimbursement has already gotten in the way of the growth of its Alair
bronchial thermoplasty system and now it looks like the Watchman LAA
device will be coming to market a year later than expected, if the FDA
lets it go to market at all.
Continue here to the full article:
Boston's Watchman Under New FDA Scrutiny
No comments:
Post a Comment